Abstract
Objective: To explore the effect of TCD foaming test in screening patent foramen ovale in migraine patients, as well as in the treatment effect. Methods: From September 2019 to August 2020, 236 patients with migraine and 362 patients with normal physical examination were treated in our hospital. According to the random number table method, 60 patients with migraine were selected as the observation group, and 60 patients with normal physical examination were selected as the control group. 48 cases of PFO were confirmed by TCD foaming test Among the patients with migraine, 36 patients received interventional occlusion therapy. The therapeutic effect and VAS score of the two groups were analyzed. Results: Through TCD foaming test, the proportion of PFO in the observation group was 80%, and that in the control group was 13.33%. The proportion of PFO in the observation group was significantly higher than that in the control group, and the difference was statistically significant (X2 = 53.5714, P < 0.01);The symptoms disappeared in 30 patients and improved in 4 patients; Among the 36 patients who received interventional occlusion therapy, the VAS score of patients before and after the operation was significantly changed, and the proportion of patients whose pain disappeared after the operation was 83.33%, which was significantly lower than that before the operation, and the difference was comparable (X2 = 51.4286, P < 0.01). Conclusion: TCD foaming test for PFO screening has strong applicability, not only safe and convenient, will not cause trauma to patients, and through interventional occlusion treatment, can significantly improve the clinical symptoms of migraine patients and cure patients.